Dose-Finding Study of SC411 in Children With Sickle Cell Disease
Status:
Active, not recruiting
Trial end date:
2022-01-02
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-finding
study of SC411 in children with sickle cell disease (SCD). The primary objective of the study
is to evaluate the safety and tolerability of three different doses of SC411 compared to a
placebo. All patients will undergo eight weeks of oral study treatment and a four-week safety
follow-up period. Patients will be randomized to one of three dose levels of SC411 or
placebo.